The success of trials that have shown net clinical benefits of antithrombotic drugs as well as
the increasing prevalence of cardiovascular diseases in an ageing population have led to …

Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to
inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and …

Direct oral anticoagulants (DOACs) are small molecule inhibitors of the coagulation
proteases thrombin and factor Xa that demonstrate comparable efficacy to warfarin for …

Introduction and aim Patient quality of life (QOL) while on long-term oral anticoagulant
therapy has been receiving greater attention in recent years due to the increase in life …

Widespread use of anticoagulant drugs for treatment and prevention of thromboembolic
events means it is common to encounter patients requiring reversal of anticoagulation for …

Background Oral anticoagulants (OACs) are very commonly prescribed for prevention of
serious vascular events, but are also associated with serious medication-related bleeding …

The management of an intracranial hemorrhage in patients receiving anticoagulant therapy
presents a significant challenge for medical professionals. Anticoagulant treatment is …

Anticoagulation therapy (AT) is fundamental in atrial fibrillation (AF) treatment but poses
challenges in implementation, especially in AF populations with elevated thromboembolic …

Abstract Background Vitamin K antagonists (VKAs), such as warfarin, have remained the
cornerstone of oral anticoagulation therapy in the prevention and treatment of …

Essentials• Tests for direct oral anticoagulants (DOACs) are not widely applied.• These tests
are perceived to be difficult to run and subjected to large between‐lab variation.• We carried …